Page 207 - 2021_02-Haematologica-web

ctDNA in cerebrospinal fluid of patients with CNS lymphoma
References
1. Yamamoto W, Tomita N, Watanabe R, et al. Central nervous system involvement in dif- fuse large B-cell lymphoma. Eur J Haematol. 2010;85(1):6-10.
2. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: IARC; 2017.
3. El-Galaly TC, Cheah CY, Bendtsen MD, et al. Treatment strategies, outcomes and prog- nostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer. 2018;93:57-68.
4. Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol. 2019;21(3):296-305.
5. Quijano S, López A, Manuel Sancho J, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol. 2009;27(9):1462-1469.
6. Hegde U, Filie A, Little RF, et al. High inci- dence of occult leptomeningeal disease detected by flow cytometry in newly diag- nosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105(2):496-502.
7. Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015;16(5):541-549.
8.Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as
early outcome predictors in diffuse large B- cell lymphoma. J Clin Oncol. 2018; 36(28):2845-2853.
9. De Mattos-Arruda L, Mayor R, Ng CKY, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839.
10. Pentsova EI, Shah RH, Tang J, et al. Evaluating cancer of the central nervous sys- tem through next-generation sequencing of cerebrospinal fluid. J Clin Oncol. 2016; 34(20):2404-2415.
11. Momtaz P, Pentsova E, Abdel-Wahab O, et al. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget. 2016;7(51):85430-85436.
12. Martínez-Ricarte F, Mayor R, Martínez-Sáez E, et al. Molecular diagnosis of diffuse gliomas through sequencing of cell-free cir- culating tumor DNA from cerebrospinal fluid. Clin Cancer Res. 2018;24(12):2812- 2819.
13. Fontanilles M, Marguet F, Bohers É, et al. Non-invasive detection of somatic muta- tions using next-generation sequencing in primary central nervous system lymphoma. Oncotarget. 2017;8(29):48157-48168.
14. Hattori K, Sakata-Yanagimoto M, Suehara Y, et al. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma. Cancer Sci. 2018;109(1):225-230.
15. Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lym-
phoma. Blood. 2019;133(5):436-445.
16. Hiemcke-Jiwa LS, Leguit RJ, Snijders TJ, et al. MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with pri- mary central nervous system lymphoma. Br
J Haematol. 2019;185(5):974-977.
17. Hiemcke-Jiwa LS, Minnema MC, Radersma-van Loon JH, et al. The use of droplet digital PCR in liquid biopsies: a high- ly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid. Hematol
Oncol. 2018;36(2):429-435.
18. Hickmann AK, Frick M, Hadaschik D, et al.
Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulat- ing tumor DNA in patients with central nervous system lymphomas. BMC Cancer. 2019;19(1):192.
19.Rimelen V, Ahle G, Pencreach E, et al. Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis. Acta Neuropathol Commun. 2019;7(1):43.
20. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra168.
21. Langner-Lemercier S, Houillier C, Soussain C, et al. Primary CNS lymphoma at first relapse/progression: characteristics, man- agement, and outcome of 256 patients from the French LOC network. Neuro Oncol. 2016;18(9):1297-1303.
22. Canovi S, Campioli D. Accuracy of flow cytometry and cytomorphology for the diagnosis of meningeal involvement in lym- phoid neoplasms: a systematic review. Diagn Cytopathol. 2016;44(10):841-856.
haematologica | 2021; 106(2)
521